Advertisement

New Neoadjuvant Chemotherapy for Resectable Liver Metastases of Colorectal Cancer

  • Antoine Brouquet
  • Stéphane Benoist
  • Bernard Nordlinger
Chapter

Abstract

Surgical resection is the only method for treating colorectal liver metastases, because it can ensure long-term survival and cure in some patients. Only approximately 20 % of colorectal cancer patients with liver metastases can undergo liver resection at the time of diagnosis. Modern chemotherapy regimens are received by other patients, which could achieve high response rates but are insufficient for cure. Recurrences are observed in the majority of patients who undergo liver resection despite developed surgical technique and improved surgical skills. Many patients with resectable metastases undergo neoadjuvant chemotherapy before liver resection. Its benefit in terms of long-term disease control has been recently demonstrated, but neoadjuvant chemotherapy has also potential disadvantages, in particular chemotherapy-associated liver injury.

Keywords

Liver Metastasis Preoperative Chemotherapy Colorectal Liver Metastasis Tumor Regression Grade Undergo Liver Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225 [Epub ahead of print].CrossRefPubMedGoogle Scholar
  2. 2.
    Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23:2038–48.CrossRefPubMedGoogle Scholar
  5. 5.
    Nordlinger B, Jaeck D, Guiguet M, Vaillant JC, Balladur P, Schaal JC. Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordlinger B, Jaeck D, editors. Treatment of hepatic metastases of colorectal cancer. Paris: Springer; 1992. p. 129–46.CrossRefGoogle Scholar
  6. 6.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Scheele J. Hepatectomy for liver metastases. Br J Surg. 1993;80:274–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases. Ann Surg. 1998;228:756–62.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–48.CrossRefPubMedGoogle Scholar
  11. 11.
    Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol. 2002;20:1499–505.CrossRefPubMedGoogle Scholar
  12. 12.
    Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Langer B, Bleiberg H, Labianca R. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. J Clin Oncol. 2002;20:149a. abstr 592.Google Scholar
  14. 14.
    Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. J Clin Oncol. 2006;24(18S):3524.Google Scholar
  15. 15.
    Ychou M, Hohenberger W, Thezenas S, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (CPT-GMA-301). J Clin Oncol. 2008;26:LBA4013.Google Scholar
  16. 16.
    Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003;90:963–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–15.CrossRefPubMedGoogle Scholar
  18. 18.
    Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–61.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.CrossRefPubMedGoogle Scholar
  20. 20.
    Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Blazer 3rd DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145:362–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol. 2006;24:4954–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer. 1998;77:2008–11.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;24:118–24.CrossRefGoogle Scholar
  31. 31.
    Nordlinger B, Sorbye H, Glimelius B, EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD), et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46.CrossRefPubMedGoogle Scholar
  33. 33.
    Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939–45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht and People's Medical Publishing House 2017

Authors and Affiliations

  • Antoine Brouquet
    • 1
    • 2
  • Stéphane Benoist
    • 1
    • 2
  • Bernard Nordlinger
    • 1
    • 2
    • 3
  1. 1.Assistance Publique Hôpitaux de Paris, Université de VersaillesVersaillesFrance
  2. 2.Hôpital Ambroise ParéBoulogneFrance
  3. 3.Service de Chirurgie DigestiveHôpital Ambroise ParéBoulogne CedexFrance

Personalised recommendations